Pharmaceuticals

With synthetic opioids lurking, DNA detector scores

By GREGORY ZELLER // With synthetic opioids increasingly implicated in the alarming number of drug-overdose deaths plaguing the nation, a stalwart Long Island biotech’s DNA-based tracking technology has received a major endorsement. The peer-reviewed scientific journal PLOS ONE has published a paper by Stony Brook-based Applied DNA Sciences on the molecular tagging of pharmaceuticals – a next-gen supply-chain authenticator that Applied DNA considers unforgeable, inescapable and particularly useful in a world where counterfeit drugs are…


Stakeholders unite to support pharma/nutra’s future

By GREGORY ZELLER // With more than 150 companies and 9,800-plus employees, the pharmaceutical/nutraceutical industry is already a Long Island cornerstone – and some major regional stakeholders want to see it grow. On Tuesday, the Suffolk County Industrial Development Agency and the Workforce Development Institute officially introduced “Driving Suffolk County’s Innovation Economy: The Pharmaceutical/Nutraceutical Growth Factor,” a 48-page report detailing pharma/nutra’s impressive growth over the last decade and the unique obstacles the industry faces on…


Memo to Applied DNA: It’s payday in Pennsylvania

By GREGORY ZELLER // Memorandums of understanding are swell and all, but for a scrappy enterprise forever waging a bottom-line battle, nothing beats getting paid. So, Stony Brook-based Applied DNA Sciences should be very happy to receive the first of two “milestone payments” accompanying the March 31 signing of a new licensing deal with Pennsylvania manufacturer Colorcon Inc. Announced Thursday, the license and cooperation agreement grants Colorcon the exclusive worldwide right to add Applied DNA’s…


Pharm hand: Why Rechler Equity is big on biotech

By GREGORY ZELLER // Anyone still doubting the importance of the pharmaceutical and biotech industries to the Long Island economy should take a peek at Rechler Equity Partners’ portfolio. This branch of the royal family of LI real estate didn’t set out to anchor its commercial holdings with biotech tenants, but over the last decade-plus, “it happened organically,” noted Mitchell Rechler, who co-manages the Plainview-based real estate giant – and its 6 million square feet…